{"result": "(\"entity\"<|>DESVIAT LR<|>PERSON<|>Desviat LR is an author who contributed to research on the relationship between mutation genotype and biochemical phenotype in phenylketonuria populations.)\n##\n(\"entity\"<|>PÉREZ B<|>PERSON<|>Pérez B is an author involved in the study of phenylketonuria and its biochemical aspects.)\n##\n(\"entity\"<|>GARCÍA MJ<|>PERSON<|>García MJ is an author who co-authored research on phenylketonuria.)\n##\n(\"entity\"<|>MARTINEZ-PARDO M<|>PERSON<|>Martinez-Pardo M is an author who contributed to the understanding of phenylketonuria and its treatment.)\n##\n(\"entity\"<|>BALDELLOU A<|>PERSON<|>Baldellou A is an author who has researched phenylketonuria and its management.)\n##\n(\"entity\"<|>ARENA J<|>PERSON<|>Arena J is an author who has contributed to studies on phenylketonuria.)\n##\n(\"entity\"<|>ZURFLUH MR<|>PERSON<|>Zurfluh MR is an author who has researched molecular genetics related to phenylketonuria.)\n##\n(\"entity\"<|>ZSCHOCKE J<|>PERSON<|>Zschocke J is an author involved in the study of phenylketonuria and its genetic factors.)\n##\n(\"entity\"<|>LINDNER M<|>PERSON<|>Lindner M is an author who has contributed to research on phenylketonuria.)\n##\n(\"entity\"<|>FEILLET F<|>PERSON<|>Feillet F is an author who has researched tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency.)\n##\n(\"entity\"<|>CHERY C<|>PERSON<|>Chery C is an author involved in the study of phenylketonuria.)\n##\n(\"entity\"<|>BURLINA A<|>PERSON<|>Burlina A is an author who has researched phenylketonuria and its treatment options.)\n##\n(\"entity\"<|>DOBROWOLSKI SF<|>PERSON<|>Dobrowolski SF is an author who has studied biochemical characterization related to phenylketonuria.)\n##\n(\"entity\"<|>PEY AL<|>PERSON<|>Pey AL is an author who has contributed to research on phenylketonuria.)\n##\n(\"entity\"<|>KOCH R<|>PERSON<|>Koch R is an author involved in the study of phenylketonuria.)\n##\n(\"entity\"<|>LEVY H<|>PERSON<|>Levy H is an author who has researched phenylketonuria and its management.)\n##\n(\"entity\"<|>ELLINGSON CC<|>PERSON<|>Ellingson CC is an author who has contributed to studies on phenylketonuria.)\n##\n(\"entity\"<|>NAYLOR EW<|>PERSON<|>Naylor EW is an author involved in research on phenylketonuria.)\n##\n(\"entity\"<|>SANJURJO P<|>PERSON<|>Sanjurjo P is an author who has contributed to the understanding of metabolic diseases, including phenylketonuria.)\n##\n(\"entity\"<|>MAILLOT F<|>PERSON<|>Maillot F is an author who has researched factors influencing outcomes in phenylketonuria.)\n##\n(\"entity\"<|>LILBURN M<|>PERSON<|>Lilburn M is an author involved in the study of phenylketonuria.)\n##\n(\"entity\"<|>BAUDIN J<|>PERSON<|>Baudin J is an author who has contributed to research on phenylketonuria.)\n##\n(\"entity\"<|>MORLEY DW<|>PERSON<|>Morley DW is an author involved in the study of phenylketonuria.)\n##\n(\"entity\"<|>LEE PJ<|>PERSON<|>Lee PJ is an author who has researched phenylketonuria.)\n##\n(\"entity\"<|>DING Z<|>PERSON<|>Ding Z is an author who has contributed to studies on phenylketonuria.)\n##\n(\"entity\"<|>HARDING CO<|>PERSON<|>Harding CO is an author involved in research on phenylketonuria.)\n##\n(\"entity\"<|>REBUFFAT A<|>PERSON<|>Rebuffat A is an author who has studied phenylketonuria.)\n##\n(\"entity\"<|>ELZAOUK L<|>PERSON<|>Elzaouk L is an author involved in research on phenylketonuria.)\n##\n(\"entity\"<|>WOLFF JA<|>PERSON<|>Wolff JA is an author who has contributed to studies on phenylketonuria.)\n##\n(\"entity\"<|>THONY B<|>PERSON<|>Thony B is an author involved in research on phenylketonuria.)\n##\n(\"entity\"<|>MCLEOD E<|>PERSON<|>McLeod E is an author who has researched nutritional treatment for phenylketonuria.)\n##\n(\"entity\"<|>NEY D<|>PERSON<|>Ney D is an author involved in the study of phenylketonuria.)\n##\n(\"entity\"<|>AL HAFID NA<|>PERSON<|>Al Hafid NA is an author who has reviewed current and future treatments for phenylketonuria.)\n##\n(\"entity\"<|>CHRISTODOULOU J<|>PERSON<|>Christodoulou J is an author involved in research on phenylketonuria.)\n##\n(\"entity\"<|>MARTINEZ-PARDO M<|>PERSON<|>Martinez-Pardo M is an author who has contributed to the protocol for diagnosing and treating hyperphenylalaninemias.)\n##\n(\"entity\"<|>BELANGUER-QUINTANA A<|>PERSON<|>Bélanguer-Quintana A is an author involved in research on phenylketonuria.)\n##\n(\"entity\"<|>GARCÍA MUÑOZ M<|>PERSON<|>García Muñoz M is an author who has contributed to studies on phenylketonuria.)\n##\n(\"entity\"<|>UGARTE M<|>PERSON<|>Ugarte M is an author involved in research on phenylketonuria.)\n##\n(\"entity\"<|>MOREIRAS O<|>PERSON<|>Moreiras O is an author who has published a table of food composition relevant to dietary management of phenylketonuria.)\n##\n(\"entity\"<|>FREIBURG<|>GEO<|>Freiburg is a city in Germany where the EMG Workshop Proceedings on metabolic disorders, including phenylketonuria, were held.)\n##\n(\"entity\"<|>EMG WORKSHOP<|>EVENT<|>The EMG Workshop is a conference that discusses metabolic disorders, including phenylketonuria.)\n##\n(\"entity\"<|>GENETIC METABOLISM<|>ORGANIZATION<|>Genetic Metabolism is a journal that publishes research on metabolic disorders, including phenylketonuria.)\n##\n(\"relationship\"<|>DESVIAT LR<|>PHENYLKETONURIA<|>Desviat LR has researched the relationship between mutation genotype and biochemical phenotype in phenylketonuria<|>7)\n##\n(\"relationship\"<|>PÉREZ B<|>PHENYLKETONURIA<|>Pérez B has contributed to studies on phenylketonuria<|>7)\n##\n(\"relationship\"<|>GARCÍA MJ<|>PHENYLKETONURIA<|>García MJ has co-authored research related to phenylketonuria<|>7)\n##\n(\"relationship\"<|>MARTINEZ-PARDO M<|>PHENYLKETONURIA<|>Martinez-Pardo M has contributed to the understanding of phenylketonuria<|>7)\n##\n(\"relationship\"<|>BALDELLOU A<|>PHENYLKETONURIA<|>Baldellou A has researched phenylketonuria and its management<|>7)\n##\n(\"relationship\"<|>ARENA J<|>PHENYLKETONURIA<|>Arena J has contributed to studies on phenylketonuria<|>7)\n##\n(\"relationship\"<|>ZURFLUH MR<|>PHENYLKETONURIA<|>Zurfluh MR has researched molecular genetics related to phenylketonuria<|>7)\n##\n(\"relationship\"<|>ZSCHOCKE J<|>PHENYLKETONURIA<|>Zschocke J has studied genetic factors associated with phenylketonuria<|>7)\n##\n(\"relationship\"<|>LINDNER M<|>PHENYLKETONURIA<|>Lindner M has contributed to research on phenylketonuria<|>7)\n##\n(\"relationship\"<|>FEILLET F<|>PHENYLKETONURIA<|>Feillet F has researched tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, related to phenylketonuria<|>7)\n##\n(\"relationship\"<|>CHERY C<|>PHENYLKETONURIA<|>Chery C has contributed to studies on phenylketonuria<|>7)\n##\n(\"relationship\"<|>BURLINA A<|>PHENYLKETONURIA<|>Burlina A has researched treatment options for phenylketonuria<|>7)\n##\n(\"relationship\"<|>DOBROWOLSKI SF<|>PHENYLKETONURIA<|>Dobrowolski SF has studied biochemical characterization related to phenylketonuria<|>7)\n##\n(\"relationship\"<|>PEY AL<|>PHENYLKETONURIA<|>Pey AL has contributed to research on phenylketonuria<|>7)\n##\n(\"relationship\"<|>KOCH R<|>PHENYLKETONURIA<|>Koch R has studied phenylketonuria<|>7)\n##\n(\"relationship\"<|>LEVY H<|>PHENYLKETONURIA<|>Levy H has researched management strategies for phenylketonuria<|>7)\n##\n(\"relationship\"<|>ELLINGSON CC<|>PHENYLKETONURIA<|>Ellingson CC has contributed to studies on phenylketonuria<|>7)\n##\n(\"relationship\"<|>NAYLOR EW<|>PHENYLKETONURIA<|>Naylor EW has researched phenylketonuria<|>7)\n##\n(\"relationship\"<|>SANJURJO P<|>PHENYLKETONURIA<|>Sanjurjo P has contributed to the understanding of metabolic diseases, including phenylketonuria<|>7)\n##\n(\"relationship\"<|>MAILLOT F<|>PHENYLKETONURIA<|>Maillot F has researched factors influencing outcomes in phenylketonuria<|>7)\n##\n(\"relationship\"<|>LILBURN M<|>PHENYLKETONURIA<|>Lilburn M has contributed to studies on phenylketonuria<|>7)\n##\n(\"relationship\"<|>BAUDIN J<|>PHENYLKETONURIA<|>Baudin J has researched phenylketonuria<|>7)\n##\n(\"relationship\"<|>MORLEY DW<|>PHENYLKETONURIA<|>Morley DW has studied phenylketonuria<|>7)\n##\n(\"relationship\"<|>LEE PJ<|>PHENYLKETONURIA<|>Lee PJ has contributed to research on phenylketonuria<|>7)\n##\n(\"relationship\"<|>DING Z<|>PHENYLKETONURIA<|>Ding Z has studied phenylketonuria<|>7)\n##\n(\"relationship\"<|>HARDING CO<|>PHENYLKETONURIA<|>Harding CO has contributed to research on phenylketonuria<|>7)\n##\n(\"relationship\"<|>REBUFFAT A<|>PHENYLKETONURIA<|>Rebuffat A has studied phenylketonuria<|>7)\n##\n(\"relationship\"<|>ELZAOUK L<|>PHENYLKETONURIA<|>Elzaouk L has contributed to studies on phenylketonuria<|>7)\n##\n(\"relationship\"<|>WOLFF JA<|>PHENYLKETONURIA<|>Wolff JA has researched phenylketonuria<|>7)\n##\n(\"relationship\"<|>THONY B<|>PHENYLKETONURIA<|>Thony B has contributed to research on phenylketonuria<|>7)\n##\n(\"relationship\"<|>MCLEOD E<|>PHENYLKETONURIA<|>McLeod E has researched nutritional treatment for phenylketonuria<|>7)\n##\n(\"relationship\"<|>NEY D<|>PHENYLKETONURIA<|>Ney D has studied phenylketonuria<|>7)\n##\n(\"relationship\"<|>AL HAFID NA<|>PHENYLKETONURIA<|>Al Hafid NA has reviewed treatments for phenylketonuria<|>7)\n##\n(\"relationship\"<|>CHRISTODOULOU J<|>PHENYLKETONURIA<|>Christodoulou J has contributed to research on phenylketonuria<|>7)\n##\n(\"relationship\"<|>MARTINEZ-PARDO M<|>PHENYLKETONURIA<|>Martinez-Pardo M has contributed to the protocol for diagnosing and treating hyperphenylalaninemias<|>7)\n##\n(\"relationship\"<|>BELANGUER-QUINTANA A<|>PHENYLKETONURIA<|>Bélanguer-Quintana A has researched phenylketonuria<|>7)\n##\n(\"relationship\"<|>GARCÍA MUÑOZ M<|>PHENYLKETONURIA<|>García Muñoz M has contributed to studies on phenylketonuria<|>7)\n##\n(\"relationship\"<|>UGARTE M<|>PHENYLKETONURIA<|>Ugarte M has researched phenylketonuria<|>7)\n##\n(\"relationship\"<|>MOREIRAS O<|>PHENYLKETONURIA<|>Moreiras O has published a table of food composition relevant to dietary management of phenylketonuria<|>7)\n##\n(\"relationship\"<|>FREIBURG<|>EMG WORKSHOP<|>Freiburg is the location where the EMG Workshop on metabolic disorders, including phenylketonuria, was held<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: -mia. Phenylalanine hydroxylase deficiency.The metabolic and molecular bases of inherited disease. McGraw Hill; Chapter 77, 2008\n3. Desviat LR, Pérez B, García MJ, Martinez-Pardo M, Baldellou A, Arena J, et al. Relationship between mutation genotype and biochemical phenotype in a heterogeneous Spanish phenylketonuria population.Eur J Hum Genet 1997; 5: 196-202.\n4. Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria.Arch Dis Child 1990; 65: 472-8.\n5. Maillot F, Lilburn M, Baudin J, Morley DW, Lee PJ. Factors influencing outcomes in the offspring of mothers with Phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. Am J Clin Nutr 2008; 88:700-5\n6. Zurfluh MR, Zschocke J, Lindner M, Feillet F, Chery C, Burlina A, et al. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat 2008; 29: 167-75.\n7. Dobrowolski SF, Pey AL, Koch R, Levy H, Ellingson CC, Naylor EW, et al. Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients. J Inherit Metab Dis 2009; 32: 10-21.\n8. Sanjurjo P. Actualización en Enfermedades Raras Metabólicas. XI Reunión Asociación de Neurociencias del Desarrollo, Cádiz, mayo 2013.\n9. Ding Z, Harding CO, Rebuffat A, Elzaouk L, Wolff JA, Thony B. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol Ther 2008; 16 (4): 673-81\n10. McLeod E, Ney D. Tratamiento nutricional de la fenilcetonuria. Ann Nestlé (Esp). 2010; 68: 60-71\n11. Ney DM, Blank RD, Hansen KE. Advances in the nutritional and pharmacological management of Phenylketonuria.Curr Opin Clin Nutr Metab Care. 2014; 17: 61-68\n12. Al Hafid NA, Christodoulou J. Phenylketonuria: a review of current and future treatments. Transl Pediatr 2015; 4(4): 304-17.\n13. Martinez-Pardo M, Bélanguer-Quintana A, García Muñoz M, Desviat L, Pérez B, Ugarte M. Protocolo de diagnóstico, tratamiento y seguimiento de las hiperfenilalaninemias. 2016; 71-108.\n14. Moreiras O. Tabla composición alimentos. 16ª ed. Madrid: Pirámide; 2013\n15. Fenilcetonuria- Nutricia (Internet). Nutricia. es.2016. Available from: http://www.nutricia.es/ areas-terapeuticas/fenilcetonuria-pku/\n16. Wappner RS, Gibson KM. Disorders of leucine metabolism. En: Blau N, Hoffmann GF, Leonard J, Clarke JJR (eds). Physician's guide to the treatment and follow-up of metabolic diseases.Berlín: Springer-Verlag; 2006. p. 59-79\n17. Dalmau Serra J, Fernández Sánchez A, Sánchez-Valverde Visus F, Vitoria Miñana I. Enfermedad de orina de jarabe de arce. En Sanjurjo P, Baldellou A (ed). Diagnóstico y tratamiento de las Enfermedades Metabólicas Hereditarias.3ª ed. Madrid, Ergon 2009. p. 489-498\n18. Ruiz Pons M, Sánchez-Valverde Visus F, Dalmau Serra J, Gómez López L. Tratamiento nutricional de los errores innatos del metabolismo. 2ª ed; 4: 175-194.\n---\nTema 18. Soporte nutricional en metabolopatías de los aminoácidos... 321\n\n19. Santer R, Harnacke K, Burlina A. MSUD-From diet to liver transplantation. EMG Workshop Procce-dings , Freiburg, 2016.\n\n20. Burrage LC, Jain M, Gandolfo L, Lee BH. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Genet Metab 2014; 113 (1-2):131-5.\n\n21. Miles EW, Kraus JP. Cystathionine b-synthase: Structure, Function, Regulation, and Location of Homocystinuria causing Mutations. Journal of Biological Chemistry 2004; 279 (29): 29871-29874.\n\n22. Kniffin CL. Homocystinuria due to cystathionine beta-synthase deficiency. OMIM© – Online Men-delian Inheritance in Man©.Actualizado 10/11/2010.Consultado 7/1/201\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>PHENYLKETONURIA<|>EVENT<|>Phenylketonuria is a metabolic disorder caused by a deficiency in phenylalanine hydroxylase, leading to an accumulation of phenylalanine in the body, which can cause serious health issues if not managed properly.)\n##\n(\"entity\"<|>NUTRICIA<|>ORGANIZATION<|>Nutricia is an organization that provides nutritional support and products for individuals with metabolic disorders, including phenylketonuria.)\n##\n(\"entity\"<|>CADIZ<|>GEO<|>Cádiz is a city in Spain where the XI Reunión Asociación de Neurociencias del Desarrollo took place, focusing on rare metabolic diseases.)\n##\n(\"entity\"<|>SPAIN<|>GEO<|>Spain is the country where the studies and treatments related to phenylketonuria are being researched and discussed.)\n##\n(\"entity\"<|>XI REUNIÓN ASOCIACIÓN DE NEUROCIENCIAS DEL DESARROLLO<|>EVENT<|>The XI Reunión Asociación de Neurociencias del Desarrollo is a conference held in Cádiz, Spain, focusing on the latest research and developments in the field of neuroscience and metabolic diseases.)\n##\n(\"entity\"<|>MAYO 2013<|>EVENT<|>Mayo 2013 refers to the month and year when the XI Reunión Asociación de Neurociencias del Desarrollo was held.)\n##\n(\"entity\"<|>AMERICAN JOURNAL OF CLINICAL NUTRITION<|>ORGANIZATION<|>The American Journal of Clinical Nutrition publishes research related to nutritional science, including studies on dietary treatment for phenylketonuria.)\n##\n(\"entity\"<|>EUROPEAN JOURNAL OF HUMAN GENETICS<|>ORGANIZATION<|>The European Journal of Human Genetics publishes research on genetic disorders, including studies on phenylketonuria and its genetic basis.)\n##\n(\"entity\"<|>HUMAN MUTATION<|>ORGANIZATION<|>Human Mutation is a journal that focuses on the study of mutations and their effects on human health, including conditions like phenylketonuria.)\n##\n(\"entity\"<|>NUTRITIONAL MANAGEMENT<|>EVENT<|>Nutritional management refers to the dietary strategies and treatments developed for managing phenylketonuria.)\n##\n(\"relationship\"<|>NUTRICIA<|>PHENYLKETONURIA<|>Nutricia provides nutritional support specifically for individuals with phenylketonuria, helping to manage the disorder through diet<|>8)\n##\n(\"relationship\"<|>XI REUNIÓN ASOCIACIÓN DE NEUROCIENCIAS DEL DESARROLLO<|>PHENYLKETONURIA<|>The conference in Cádiz focused on research and discussions related to phenylketonuria and other metabolic disorders<|>6)\n##\n(\"relationship\"<|>XI REUNIÓN ASOCIACIÓN DE NEUROCIENCIAS DEL DESARROLLO<|>CADIZ<|>The XI Reunión Asociación de Neurociencias del Desarrollo was held in Cádiz, Spain<|>7)\n##\n(\"relationship\"<|>EUROPEAN JOURNAL OF HUMAN GENETICS<|>PHENYLKETONURIA<|>The journal publishes research articles that include studies on the genetic aspects of phenylketonuria<|>7)\n##\n(\"relationship\"<|>AMERICAN JOURNAL OF CLINICAL NUTRITION<|>PHENYLKETONURIA<|>The journal features studies on dietary treatments for phenylketonuria, contributing to the understanding of nutritional management<|>7)\n##\n(\"relationship\"<|>HUMAN MUTATION<|>PHENYLKETONURIA<|>The journal discusses mutations related to phenylketonuria, providing insights into its genetic causes<|>7)\n##\n(\"relationship\"<|>NUTRITIONAL MANAGEMENT<|>PHENYLKETONURIA<|>Nutritional management is essential for individuals with phenylketonuria to control their phenylalanine levels<|>9)\n<|COMPLETE|>"}]}